These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9652632)

  • 1. Canadian hopes for low-cost drugs dashed.
    Kondro W
    Lancet; 1998 Jan; 351(9099):350. PubMed ID: 9652632
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry.
    Hore E
    Food Drug Law J; 2000; 55(3):373-88. PubMed ID: 11824466
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 4. Generic drug companies are the winners.
    Voth AJ
    CMAJ; 1991 Nov; 145(9):1081. PubMed ID: 1751924
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 7. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 8. Canada's Amendment to Patented Drug Price Regulation: A Prescription for Global Drug Cost Control?
    Humphries B; Xie F
    JAMA; 2019 Apr; 321(16):1565-1566. PubMed ID: 30924840
    [No Abstract]   [Full Text] [Related]  

  • 9. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 10. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
    Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 12. Patenting ESTs: is it worth it?
    Nat Genet; 1999 Feb; 21(2):145-6. PubMed ID: 9988257
    [No Abstract]   [Full Text] [Related]  

  • 13. [Why patent-protected drugs' cost efficiency should be compared with generic preparations].
    Berggren F; Lundin D; Ramsberg J
    Lakartidningen; 2006 Jan 25-31; 103(4):223-4. PubMed ID: 16491555
    [No Abstract]   [Full Text] [Related]  

  • 14. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
    Vandergrift M; Kanavos P
    Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reforming Canada's Access to Medicines Regime.
    Esmail LC
    CMAJ; 2007 Jul; 177(3):270. PubMed ID: 17664454
    [No Abstract]   [Full Text] [Related]  

  • 16. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 17. A tragically naive Canadian law for tragically neglected global health.
    Attaran A
    CMAJ; 2007 Jun; 176(12):1726-7. PubMed ID: 17449707
    [No Abstract]   [Full Text] [Related]  

  • 18. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 20. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.